Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer

被引:24
|
作者
Eissa, S [1 ]
Labib, RA
Mourad, MS
Kamel, K
El-Ahmady, O
机构
[1] Ain Shams Univ, Fac Med, Dept Biochem, Oncol Diagnost Unit, Cairo, Egypt
[2] Ain Shams Univ, Fac Med, Dept Urol, Cairo, Egypt
[3] Ain Shams Univ, Fac Med, Early Canc Detect Unit, Cairo, Egypt
[4] Ain Shams Univ, Fac Pharm, Dept Biochem, Cairo, Egypt
关键词
bladder cancer (BC); urine cytology (UC); bladder wash (BW); telomerase activity; MMP-9; bilharziasis;
D O I
10.1016/S0302-2838(03)00417-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: This study was undertaken to evaluate the diagnostic efficacy of telomerase in urine, and bladder wash and also the matrix metalloproteinase-9 (MMP-9) in urine, compared with voided urine cytology (VUC) and bladder wash cytology (BWC) for the detection of bladder cancer cells. Material and Methods: A total of 110 subjects provided a single preoperative voided morning urine sample for telomerase, matrix metalloproteinase-9 (MMP-9) and cytology. Bladder wash samples were obtained for telomerase and cytology. Cystoscopy was done for all patients as the reference standard for the identification of bladder cancer. Biopsy of any suspicious lesion was performed for histopathological examination. Of 110 cases 73 were histologically diagnosed as bladder cancer, whereas the remaining 16 had benign urological disorders. A group of 21 healthy volunteers were also enrolled in this study. Results: The optimal threshold values for telomerase activity in urine, bladder wash and MMP-9 were calculated by receiver-operator characteristics (ROC) curves as 0.05, 0.088 and 0.51 (ng/ml), respectively. The levels and the positivity rates of the 2 parameters were significantly higher in the malignant group compared to either the benign group or normal controls. Of the entire group, telomerase activity in urine, bladder wash, and MMP-9 were positive in 92%, 87% and 61%, respectively in bladder cancer patients with positive cytology. Moreover, these positive rates for them were significantly higher in bilharzial bladder cancer cases (88%, 89%, 69%, respectively) compared to non-bilharzial cases (50%, 62.5%, 50%). The overall sensitivity and specificity were 83% and 88.6%, 86.3% and 78.3% for telomerase activity in urine, and in bladder wash, respectively; 66.6% and 80% for MMP-9 and 58.5% and 100% for voided urine cytology and 64.4% and 100% for bladder wash cytology. Combined sensitivity of VUC with the 2 biomarkers together was higher than either combined sensitivity of VUC with one of the biomarkes or than that of the biomarker alone. Conclusions: Our data indicate that urinary telomerase and MMP-9 had superior sensitivities over VUC. The combined use of markers increased the sensitivity of cytology from 58.46% to 95%. The higher sensitivities of markers in bilharzial bladder cancer than non-bilharzial type highlight their clinical utility in screening patients with urinary bilharziasis. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:687 / 694
页数:8
相关论文
共 50 条
  • [31] URINARY MATRIX METALLOPROTEINASE-9 AS A POTENTIAL BIOMARKER FOR INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME
    Argade, Shilpa
    Kashyap, Mahendra
    Chermansky, Christopher
    Ganabathi, Kumaresan
    Olonski, Janet
    Tyagi, Pradeep
    JOURNAL OF UROLOGY, 2016, 195 (04): : E954 - E955
  • [32] Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder
    Candido, Saverio
    Di Maso, Matteo
    Serraino, Diego
    McCubrey, James A.
    Bortolus, Roberto
    Zanin, Martina
    Battiston, Monica
    Salemi, Rossella
    Libra, Massimo
    Polesel, Jerry
    TUMOR BIOLOGY, 2016, 37 (07) : 9855 - 9863
  • [33] Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients
    Casadio, Valentina
    Bravaccini, Sara
    Gunelli, Roberta
    Nanni, Oriana
    Zoli, Wainer
    Amadori, Dino
    Calistri, Daniele
    Silvestrini, Rosella
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2009, 24 (04): : 253 - 257
  • [34] Detection of telomerase in urine by 3 methods: Evaluation of diagnostic accuracy for bladder cancer
    Eissa, Sanaa
    Swellam, Menha
    Ali-Labib, Randa
    Mansour, Aml
    El-Malt, Osama
    Tash, Fathy Mohamed
    JOURNAL OF UROLOGY, 2007, 178 (03): : 1068 - 1072
  • [35] Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors
    Eissa, S
    Swellam, M
    Sadek, M
    Mourad, MS
    Ahmady, OE
    Khalifa, A
    JOURNAL OF UROLOGY, 2002, 168 (02): : 465 - 469
  • [36] BTA-TRAK™ -: A useful diagnostic tool in urinary bladder cancer?
    Mahnert, B
    Tauber, S
    Kriegmair, M
    Schmitt, UM
    Hashholzner, U
    Reiter, W
    Hofmann, K
    Schmeller, N
    Stieber, P
    ANTICANCER RESEARCH, 1999, 19 (4A) : 2615 - 2619
  • [37] hTERT mRNA expression in urine as a useful diagnostic tool in bladder cancer. Comparison with cytology and NMP22 BladderCheck Test®
    March-Villalba, J. A.
    Panach-Navarrete, J.
    Herrero-Cervera, M. J.
    Alino-Pellicer, S.
    Martinez-Jabaloyas, J. M.
    ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (08): : 524 - 530
  • [38] Expression of matrix metalloproteinase-9 in tumor-associated macrophages in transitional cell carcinoma of the bladder
    Brands, FH
    Schneider, B
    Pannek, J
    Senge, T
    Hofmockel, G
    JOURNAL OF UROLOGY, 2002, 167 (04): : 117 - 117
  • [39] MATRIX METALLOPROTEINASE-9 CONTROLS SECRETION OF NERVE GROWTH FACTOR FROM BLADDER CELLS IN VITRO
    Hajj, Aya
    Hamouda, Aalya
    Sirmakesyan, Stephanie
    Cammisotto, Philippe
    Campeau, Lysanne
    JOURNAL OF UROLOGY, 2022, 207 (05): : E854 - E854
  • [40] Comparison of telomerase activity in bladder carcinoma and exfoliated cells collected in urine and bladder washings, using a quantitative assay
    Gelmini, S
    Crisci, A
    Salvadori, B
    Pazzagli, M
    Selli, C
    Orlando, C
    CLINICAL CANCER RESEARCH, 2000, 6 (07) : 2771 - 2776